ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO168

Hyperphosphatemia Is Associated with Kidney Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease

Session Information

  • CKD-MBD: Clinical
    October 24, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical

Author

  • Nitta, Kosaku, Tokyo Women' Medical University, Tokyo, Shinjuku-ku, Japan
Background

The relationship between serum phosphate (P) levels and progression of kidney disease in patients with autosomal dominant polycystic kidney disease (ADPKD) remains unclear. Compared with other kidney disorders, patients with ADPKD typically have lower levels of serum P, potentially masking its clinical importance. This study sought to assess whether serum P levels can serve as a predictor of renal outcomes in ADPKD patients.

Methods

We included 235 patients with ADPKD who were not taking drugs to treat hyperphosphatemia. Survival analysis was performed for the renal outcome of a 50% reduction in estimated glomerular filtration rate (eGFR) or initiation of renal replacement therapy.

Results

The patients had mean age of 46 yeras, eGFR of 41.8 mL/min/1.73 m2, and total kidney volume (TKV) of 1254.0 mL. The median follow-up period was 10.4 years, and the renal outcome was observed in 116 patients. Multivariable Cox regression analyses revealed that serum P (1 mg/dL increase, HR=2.03, P<0.0001) was a significant risk factor associated with kidney disease progression. Similarly, hyperphosphatemia (P>4.0 mg/dL, HR=1.90, P=0.0157; P>4.5 mg/dL, HR=2.78, P=0.0047; P>5.0 mg/dL, HR=27.22, P<0.0001) was significantly associated with renal prognosis. Kaplan-Meier analysis showed that kidney survival rates were significantly lower in patients with P>3.5 mg/dL than in those without hyperphosphatemia (log-rank test, P<0.0001). The 2-year kidney survival rate of ADPKD patients with P>4.0 mg/dL was 46.8% in the entire cohort and 28.2% in patients with stage 4-5 CKD, indicating an extremely poor renal prognosis.

Conclusion

Hyperphosphatemia was associated with renal prognosis in patients with ADPKD. In these patients, attention should be paid to even mild serum P elevation of P>3.5 or P>4.0 mg/dL.